NCT03794076View on ClinicalTrials.gov

Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

January 31, 2026

Study Completion Date

June 30, 2026

Conditions
SchizophreniaSchizo Affective Disorder
Interventions
DRUG

Cromoglycate

Cromoglycate will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray

DRUG

Placebo

Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)

Trial Locations (1)

15213

RECRUITING

University of Pittsburgh, Pittsburgh

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

Vishwajit Nimgaonkar, MD PhD

OTHER